Overview Our client is a globally recognised international infrastructure group delivering major transportation and civil engineering projects across Europe and internationally. Within the organisation sits a highly specialised internal commercial and contract advisory division that operates
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)